C
C. Janneke van der Woude
Researcher at Erasmus University Rotterdam
Publications - 201
Citations - 11704
C. Janneke van der Woude is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 42, co-authored 163 publications receiving 9672 citations. Previous affiliations of C. Janneke van der Woude include Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean-Frederic Colombel,William J. Sandborn,Walter Reinisch,Gerassimos J. Mantzaris,Asher Kornbluth,Daniel Rachmilewitz,Simon Lichtiger,Robert H. Diamond,Delma L. Broussard,Kezhen L. Tang,C. Janneke van der Woude,Paul Rutgeerts +11 more
TL;DR: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Journal ArticleDOI
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche,Axel Dignass,Walter Reinisch,C. Janneke van der Woude,Andreas Sturm,Martine De Vos,Mario Guslandi,Bas Oldenburg,Iris Dotan,Philippe Marteau,Alessandro Ardizzone,Daniel C. Baumgart,Geert R. D'Haens,Paolo Gionchetti,Francisco Portela,Boris Vucelić,Johan D. Söderholm,Johanna C. Escher,Sibylle Koletzko,Kaija-Leena Kolho,Milan Lukas,Christian Mottet,Herbert Tilg,Severine Vermeire,F. Carbonnel,Andrew T. Cole,Gottfried Novacek,Max Reinshagen,Epameinondas V. Tsianos,Klaus Herrlinger,Yoram Bouhnik,Ralf Kiesslich,Eduard F. Stange,Simon Travis,James O. Lindsay +34 more
TL;DR: The aim of this Consensus was therefore critically to evaluate the optimal strategies for the management of post-operative recurrence in CD.
Journal ArticleDOI
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations.
Paolo Gionchetti,Axel Dignass,Silvio Danese,Fernando José Magro Dias,Gerhard Rogler,Peter L. Lakatos,Michel Adamina,Sandro Ardizzone,Christianne J. Buskens,Shaji Sebastian,Silvio Laureti,Gianluca M. Sampietro,Boris Vucelić,C. Janneke van der Woude,Manuel Barreiro-de Acosta,Christian Maaser,Francisco Portela,Stephan R. Vavricka,Fernando Gomollón +18 more
TL;DR: This paper concerns the surgical management of CD as well as special situations including management of perianal CD and extraintestinal manifestations.
Journal ArticleDOI
CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis
Samira Tamoutounour,Samira Tamoutounour,Samira Tamoutounour,Sandrine Henri,Sandrine Henri,Sandrine Henri,Hugues Lelouard,Hugues Lelouard,Hugues Lelouard,Béatrice de Bovis,Béatrice de Bovis,Béatrice de Bovis,Colin de Haar,C. Janneke van der Woude,Andrea M. Woltman,Yasmin Reyal,Dominique Bonnet,Dorine Sichien,Calum C. Bain,Allan McI. Mowat,Caetano Reis e Sousa,Lionel F. Poulin,Bernard Malissen,Bernard Malissen,Bernard Malissen,Martin Guilliams,Martin Guilliams,Martin Guilliams +27 more
TL;DR: It is demonstrated that, using CD64 expression, MΦs can be distinguished from DCs in the intestine of both mice and humans and how inflammation impacts this pathway is determined, and it is shown that T cell‐mediated colitis is associated with massive recruitment of monocytes to the intestine and the mesenteric lymph node (MLN).
Journal ArticleDOI
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
Mirthe E. van der Valk,Marie-Josée J. Mangen,Max Leenders,Gerard Dijkstra,Ad A. van Bodegraven,Herma H. Fidder,Dirk J. de Jong,Marieke Pierik,C. Janneke van der Woude,Mariëlle Romberg-Camps,Cees H. M. Clemens,Jeroen M. Jansen,Nofel Mahmmod,Paul C. van de Meeberg,Andrea E. van der Meulen-de Jong,Cyriel Y. Ponsioen,Clemens J. M. Bolwerk,J. Reinoud Vermeijden,Peter D. Siersema,Martijn G.H. van Oijen,Martijn G.H. van Oijen,Bas Oldenburg,Colitis +22 more
TL;DR: Assessment of healthcare costs and productivity losses in a large cohort of IBD patients showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy.